Compare EPAM Systems Inc (EPAM) vs Eli Lilly And Co (LLY) Price & Performance

EPAM trades at $98.20, up 0.85% on the day, but remains in a bearish technical trend with support near $96 and resistance at $99. The company reported strong Q2 2026 earnings of $3.38 per share, beating estimates, but lowered its full-year revenue guidance due to slower North American growth. Valuation metrics appear attractive with a P/E of 13.55 and P/S of 0.97, while profitability remains solid with a net income margin of 7.15%.

The outlook is mixed: analyst consensus is bullish with a $117.27 price target, but near-term headwinds from reduced revenue guidance and bearish technical signals pose risks. The stock offers value based on fundamentals, but investor sentiment is cautious following the guidance cut, requiring close monitoring of North American demand trends and AI partnership execution for sustained upside.

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.